These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17658091)

  • 1. Body mass index influences palpability but not stage of breast cancer at diagnosis.
    Chagpar AB; McMasters KM; Saul J; Nurko J; Martin RC; Scoggins CR; Edwards MJ
    Am Surg; 2007 Jun; 73(6):555-60; discussion 560. PubMed ID: 17658091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight correlates with mortality in early-stage breast cancer.
    Enger SM; Greif JM; Polikoff J; Press M
    Arch Surg; 2004 Sep; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
    Petráková K; Nenutil R; Grell P; Fabian P; Zichová I; Svoboda M; Palácová M; Vyzula R
    Klin Onkol; 2008; 21(5):303-8. PubMed ID: 19202962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of radiation therapy after breast-conserving surgery in hormonally treated breast cancer patients is dependent on patient age, geographic region, and surgeon specialty.
    Chagpar AB; McMasters KM; Scoggins CR; Martin RC; Thoene C; Edwards MJ
    Am J Surg; 2008 Jun; 195(6):793-8. PubMed ID: 18417083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor location of the lower-inner quadrant is associated with an impaired survival for women with early-stage breast cancer.
    Sarp S; Fioretta G; Verkooijen HM; Vlastos G; Rapiti E; Schubert H; Sappino AP; Bouchardy C
    Ann Surg Oncol; 2007 Mar; 14(3):1031-9. PubMed ID: 17176985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
    Sullivan PS; Apple SK
    Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
    Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
    Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer.
    Lumachi F; Ermani M; Marino F; Di Cristofaro L; Tombolan V; Brunello A; Roma A; Basso U
    Anticancer Res; 2008; 28(1B):491-3. PubMed ID: 18383890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen.
    Khoshnoud MR; Fornander T; Johansson H; Rutqvist LE
    Breast Cancer Res Treat; 2008 Jan; 107(1):71-8. PubMed ID: 18043896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular, and favorable histologic subtypes of breast cancer?
    Chan SW; LaVigne KA; Port ER; Fey JV; Brogi E; Borgen PI; Cody HS
    Ann Surg; 2008 Jan; 247(1):143-9. PubMed ID: 18156934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abstracting height and weight from medical records, and breast cancer pathologic factors.
    McEligot AJ; Im T; Dillman RO; West JG; Salem R; Haque R; Anton-Culver H
    Cancer Causes Control; 2008 Dec; 19(10):1217-26. PubMed ID: 18618281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age.
    Van Mieghem T; Leunen K; Pochet N; De Moor B; De Smet F; Amant F; Berteloot P; Timmerman D; Vanden Bempt I; Drijkoningen R; Wildiers H; Paridaens R; Smeets A; Hendrickx W; Van Limbergen E; Christiaens MR; Vergote I; Neven P
    Breast Cancer Res Treat; 2007 Nov; 106(1):127-33. PubMed ID: 17211534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of early distant metastatic disease in elderly patients with breast cancer.
    Chagpar AB; McMasters KM; Martin RC; Thoene C; Nurko JY; Edwards MJ;
    Am J Surg; 2006 Sep; 192(3):317-21. PubMed ID: 16920425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.